Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488807 | 1.00 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL18207821 | 0.93 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL18207448 | 0.91 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL29488805 | 0.91 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL18207675 | 0.91 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL19924970 | 0.90 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL18207665 | 0.90 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL18207528 | 0.89 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL20106767 | 0.86 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL20106966 | 0.85 | TLR7 (0.54) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111801100-B | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11337982-B2 | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor | HOFFMANN-LA ROCHE, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11337982-B2 | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor | HOFFMANN-LA ROCHE, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3970750-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. Hoffmann-La Roche AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| EP-3970750-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. Hoffmann-La Roche AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-109715214-B | Combination therapy of a TLR7 agonist and an HBV capsid assembly inhibitor | 豪夫迈·罗氏有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | disclosed |
| CN-109641904-B | 7-substituted sulfoxy-purinone compounds for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3512556-B1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN LA ROCHE (CH) | 2021-08-18 | — | — | EP | disclosed |
| WO-2018041763-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018041763-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-08 | — | — | WO | disclosed |
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9708325-B2 | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708325-B2 | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016180695-A1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016180695-A1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-17 | — | — | WO | disclosed |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | TLR7 259/4885TLR8 2038/4885 |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | TLR7 259/4885TLR8 2038/4885 |
| US-11337982-B2 | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor | TLR7, TLR9, HAVCR2 | TLR7 1/4885TLR8 9/4885 |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | STS, SULT1E1, SULT1A1 | TLR7 2510/4885TLR8 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.